Market closed
India Globalization Capital/$IGC
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About India Globalization Capital
IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer's. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.
Ticker
$IGC
Sector
Trading on
AMEX
Industry
Pharmaceuticals
Headquarters
Employees
67
Website
IGC Metrics
BasicAdvanced
$23M
-
-$0.12
1.21
-
Price and volume
Market cap
$23M
Beta
1.21
52-week high
$0.36
52-week low
$0.25
Average daily volume
363K
Financial strength
Current ratio
1.148
Quick ratio
0.212
Long term debt to equity
2.333
Total debt to equity
4.314
Management effectiveness
Return on assets (TTM)
-54.70%
Return on equity (TTM)
-115.06%
Valuation
Price to revenue (TTM)
17.089
Price to book
3.63
Price to tangible book (TTM)
5.18
Price to free cash flow (TTM)
-4.037
Growth
Revenue change (TTM)
1.64%
Earnings per share change (TTM)
-51.98%
3-year revenue growth (CAGR)
51.42%
3-year earnings per share growth (CAGR)
-19.95%
IGC News
AllArticlesVideos
IGC Pharma Expands CALMA Alzheimer's Phase 2 Trial with Prestigious Research Site at Butler Hospital's Memory and Aging Program
Accesswire·1 week ago
IGC Pharma Announces CALMA Phase 2 Trial Expansion with the Addition of Miami Jewish Health
Accesswire·2 weeks ago
IGC Pharma's Phase 2 Clinical Trial Interim Data Demonstrates Significant Reduction in Sleep Disturbances
Accesswire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for India Globalization Capital stock?
India Globalization Capital (IGC) has a market cap of $23M as of April 17, 2025.
What is the P/E ratio for India Globalization Capital stock?
The price to earnings (P/E) ratio for India Globalization Capital (IGC) stock is 0 as of April 17, 2025.
Does India Globalization Capital stock pay dividends?
No, India Globalization Capital (IGC) stock does not pay dividends to its shareholders as of April 17, 2025.
When is the next India Globalization Capital dividend payment date?
India Globalization Capital (IGC) stock does not pay dividends to its shareholders.
What is the beta indicator for India Globalization Capital?
India Globalization Capital (IGC) has a beta rating of 1.21. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.